Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Screening Test Developer New Horizon Health Goes Public in Hong Kong

NEW YORK — Chinese diagnostics firm New Horizon Health has gone public on the Hong Kong Stock Exchange, venture capital firm Qiming Venture Partners said on Thursday.

New Horizon, one of Qiming's portfolio companies, focuses on tests for early cancer screening tests and offers two fecal immunochemical tests approved in China: ColoClear for individuals at high-risk for colorectal cancer and Pupu Tube for general colorectal cancer screening.

The company is also developing a stool-based gastric cancer screening test called UU Tube and a urine-based cervical cancer screen called CerviClear, according to Qiming.

Qiming said that New Horizon's shares went public at HK$26.66 (US$3.44).

In late 2019, New Horizon partnered with Prenetics to offer ColoClear in Hong Kong and certain other Asian markets.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.